RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases.
High growth potential with mediocre balance sheet.
Share Price & News
How has RedHill Biopharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RDHL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 1.6% over the past year.
Return vs Market: RDHL underperformed the US Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is RedHill Biopharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is RedHill Biopharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RDHL ($6.86) is trading below our estimate of fair value ($81.94)
Significantly Below Fair Value: RDHL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RDHL is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: RDHL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RDHL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RDHL is overvalued based on its PB Ratio (5.5x) compared to the US Pharmaceuticals industry average (3.4x).
How is RedHill Biopharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RDHL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: RDHL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RDHL's is expected to become profitable in the next 3 years.
Revenue vs Market: RDHL's revenue (38.8% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: RDHL's revenue (38.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RDHL's Return on Equity is forecast to be high in 3 years time
How has RedHill Biopharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RDHL is currently unprofitable.
Growing Profit Margin: RDHL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RDHL is unprofitable, and losses have increased over the past 5 years at a rate of -16.7% per year.
Accelerating Growth: Unable to compare RDHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RDHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: RDHL has a negative Return on Equity (-113.62%), as it is currently unprofitable.
How is RedHill Biopharma's financial position?
Financial Position Analysis
Short Term Liabilities: RDHL's short term assets ($101.0M) exceed its short term liabilities ($17.3M).
Long Term Liabilities: RDHL's short term assets ($101.0M) exceed its long term liabilities ($82.5M).
Debt to Equity History and Analysis
Debt Level: RDHL's debt to equity ratio (179.1%) is considered high.
Reducing Debt: Insufficient data to determine if RDHL's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RDHL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RDHL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is RedHill Biopharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RDHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RDHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RDHL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RDHL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RDHL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dror Ben-Asher (54yo)
Mr. Dror Ben-Asher Co-Founded RedHill Biopharma Ltd. and has been its Chief Executive Officer since August 3, 2009. Mr. Ben-Asher serves as an Associate of Mercator Group, LLC. He has been affiliated with ...
CEO Compensation Analysis
Compensation vs Market: Dror's total compensation ($USD707.92K) is below average for companies of similar size in the US market ($USD1.34M).
Compensation vs Earnings: Dror's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||4.33yrs||US$505.51k||no data|
|Chief Operating Officer||4.25yrs||US$539.28k||no data|
|Senior Vice President of Business Development & Licensing||7.58yrs||US$504.62k||0.051% $123.5k|
|Chief Business Officer||8yrs||US$504.63k||no data|
|Chief Scientific Officer||1.17yrs||no data||0.0020% $4.9k|
|Vice President of Business Development & Communications||4.17yrs||no data||no data|
|Vice President of Sales||no data||no data||no data|
|Vice President of Marketing||1.17yrs||no data||no data|
|Senior Vice President of Research & Development||10.17yrs||US$419.98k||0.077% $185.2k|
Experienced Management: RDHL's management team is considered experienced (4.3 years average tenure).
|Chief Commercial Officer||4.5yrs||no data||no data|
|Chairman of Advisory Board||no data||no data||no data|
|Independent External Director||9.17yrs||no data||no data|
|Member of Advisory Board||1.5yrs||no data||no data|
|Director||0.83yr||no data||1.43% $3.5m|
|Member of Advisory Board||no data||no data||no data|
|Member of Advisory Board||no data||no data||no data|
|Director||10.17yrs||no data||0.30% $726.5k|
|Director||10.58yrs||no data||2.09% $5.1m|
Experienced Board: RDHL's board of directors are considered experienced (9.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.
RedHill Biopharma Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: RedHill Biopharma Ltd.
- Ticker: RDHL
- Exchange: NasdaqGM
- Founded: 2009
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$241.949m
- Shares outstanding: 35.27m
- Website: https://www.redhillbio.com
Number of Employees
- RedHill Biopharma Ltd.
- 21 Ha’arba’a Street
- Tel Aviv
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|REDI.F||OTCPK (Pink Sheets LLC)||Ordinary Shares||US||USD||Feb 2011|
|RDHL||NasdaqGM (Nasdaq Global Market)||Yes||SPONSORED ADS||US||USD||Dec 2012|
|2RH||DB (Deutsche Boerse AG)||Yes||SPONSORED ADS||DE||EUR||Dec 2012|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases. The company promotes various gastrointestinal drugs, including Movantik for opioid-induced constipation in adults; Talicia for the treatment of Helicobacter pylori bacterial infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its late-stage clinical development programs include RHB-104, which is in Phase 3 study for treating Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) that is in first Phase 3 study to treat acute gastroenteritis and gastritis, as well as has completed Phase 2 study for treating irritable bowel syndrome with diarrhea; RHB-106, which is in planned Phase 2/3 studies for bowel preparation; ABC294640 (Yeliva), a SK2 selective inhibitor, which is in Phase 1/2a study for treating cholangiocarcinoma, as well as in Phase 2 study for prostate cancer; and RHB-107 that is in planned pilot study for cholangiocarcinoma, as well as has completed Phase 2 study for gastrointestinal and other solid tumors. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/10 00:04|
|End of Day Share Price||2020/07/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.